Citius Oncology Files 8-K: Director Changes, Officer Comp, Shareholder Votes
Ticker: CTOR · Form: 8-K · Filed: Oct 27, 2025 · CIK: 1851484
Sentiment: neutral
Topics: corporate-governance, officer-compensation, director-changes
TL;DR
Citius Oncology's 8-K shows director shake-ups, new exec pay plans, and shareholder votes are happening.
AI Summary
On October 27, 2025, Citius Oncology, Inc. filed an 8-K report detailing several key events. The company announced the departure of a director, the election of a new director, and changes to compensatory arrangements for certain officers. Additionally, the filing covers the submission of matters to a vote of security holders and includes financial statements and exhibits.
Why It Matters
This filing indicates significant corporate governance and executive compensation adjustments, which could impact investor confidence and the company's strategic direction.
Risk Assessment
Risk Level: medium — Changes in directors and officer compensation can signal internal shifts or strategic realignments that may carry inherent business risks.
Key Numbers
- 001-41534 — SEC File Number (Identifies the company's filing with the SEC.)
- 99-4362660 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- CITIUS ONCOLOGY, INC. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- TenX Keane Acquisition (company) — Former company name
FAQ
Who departed as a director of Citius Oncology?
The filing indicates the departure of a director, but the specific name is not provided in the provided text.
When was the report filed?
The report was filed on October 27, 2025.
What are the main items covered in this 8-K filing?
The filing covers the departure of a director, election of a director, compensatory arrangements of certain officers, submission of matters to a vote of security holders, and financial statements and exhibits.
What was Citius Oncology's former name?
Citius Oncology, Inc. was formerly known as TenX Keane Acquisition.
Where is Citius Oncology, Inc. headquartered?
The company's business address is 11 Commerce Drive, 1st Floor, Cranford, NJ 07016.
Filing Stats: 711 words · 3 min read · ~2 pages · Grade level 11.2 · Accepted 2025-10-27 16:30:31
Filing Documents
- ea026265801-8k_citiusonc.htm (8-K) — 30KB
- ea026265801ex10-1_citiusonc.htm (EX-10.1) — 6KB
- 0001213900-25-102625.txt ( ) — 202KB
- ctor-20251027.xsd (EX-101.SCH) — 3KB
- ctor-20251027_lab.xml (EX-101.LAB) — 33KB
- ctor-20251027_pre.xml (EX-101.PRE) — 22KB
- ea026265801-8k_citiusonc_htm.xml (XML) — 4KB
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 27, 2025, Citius Oncology, Inc. (the "Company") held its 2025 annual meeting of stockholders (the "Annual Meeting"). At the Annual Meeting, stockholders of the Company approved an amendment to the Company's 2024 Omnibus Stock Incentive Plan (the "Amendment") increasing the number of shares of the Company's common stock authorized for issuance under the 2024 Omnibus Stock Incentive Plan from 15,000,000 to 30,000,000 shares. The Company's Board of Directors approved the Amendment on September 19, 2025, subject to stockholder approval. You can find a summary of the principal features of the Amendment in the definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission on September 26, 2025 (the "Proxy Statement"), under the heading "Proposal 2 – Approval of Amendment to the Citius Oncology, Inc. 2024 Omnibus Stock Incentive Plan". The summary of the Amendment contained in the Proxy
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. At the Annual Meeting, our stockholders elected the following Class I directors for a three-year term expiring at the annual meeting of stockholders to be held in 2028 or until their successors are duly elected and qualified, based on the following votes: Nominee For Withheld Broker Non-Votes Myron Holubiak 74,305,221 36,554 3,462,017 Joel Mayersohn 74,312,668 29,107 3,462,017 Next, at the Annual Meeting, our stockholders approved the Amendment, as described in Item 5.02 above. The vote for this proposal was 74,220,840 shares for, 106,247 shares against, 14,688 shares abstaining, and 3,462,017 broker non-votes. Finally, our stockholders ratified the selection of Wolf & Company, P.C. as our independent registered public accounting firm for the fiscal year ended September 30, 2025. The vote for such ratification was 77,690,844 shares for, 36,459 shares against, 76,489 shares abstaining, and no broker non-votes.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits The following exhibit is filed herewith: Exhibit No. Description 10.1 Amendment to the Citius Oncology, Inc. 2024 Omnibus Stock Incentive Plan. 104 Cover Page Interactive Date File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 27, 2025 CITIUS ONCOLOGY, INC. By: /s/ Leonard Mazur Leonard Mazur Chairman and Chief Executive Officer